Abnormal bone turnover in individuals with low serum alkaline phosphatase by López Delgado, Laura et al.
1 
 
ABNORMAL BONE TURNOVER IN INDIVIDUALS WITH LOW SERUM ALKALINE PHOSPHATASE 
 
Laura López-Delgado1, Leyre Riancho-Zarrabeitia*2, Maria T. García-Unzueta3,  Jair A. Tenorio4, Marta 
García-Hoyos1, Pablo Lapunzina4, Carmen Valero1 and José A. Riancho1 
 
1. Service of Internal Medicine, Hospital U.M. Valdecilla, University of Cantabria, IDIVAL. Santander, 
Spain. 
2. Service of Rheumatology. Hospital Sierrallana, Torrelavega, Spain 
3. Service of Clinical Biochemistry,  Hospital U.M. Valdecilla, University of Cantabria, IDIVAL. 
Santander, Spain. 
4. Institute of Medical and Molecular Genetics (INGEMM), Hospital Universitario La Paz. IdiPAZ. 
Universidad Autónoma de Madrid and CIBERER, ISCIII. Madrid, Spain.  
 
(*) Both authors contributed equally to this study 
 
Correspondence 
José A. Riancho 
Service of Internal Medicine, Hospital U.M. Valdecilla,  
University of Cantabria 
Av Valdecilla SN 






































































We evaluated bone mineral density (BMD), bone microarchitecture and bone turnover markers in 
patients with low serum levels of alkaline phosphatase. Our results show that these patients have low 
bone remodeling even in the absence of BMD abnormalities, thus supporting the recommendation of 







































































The clinical spectrum of hypophosphatasia (HPP) is broad and variable within families. Along 
severe infantile forms, adult forms with mild manifestations may be incidentally discovered by the 
presence of low alkaline phosphatase (ALP) activity in serum. However, it is still unclear whether 
individuals with persistently low levels of ALP, in the absence of overt manifestations of HPP, have 
subclinical abnormalities of bone remodeling or bone mass. The aim of this study was to obtain a better 
understanding of the skeletal phenotype of adults with low ALP by analyzing bone mineral density (BMD), 
bone microarchitecture (Trabecular bone score, TBS), and bone turnover markers (P1NP and ß-crosslaps).  
We studied 42 individuals with persistently low serum ALP. They showed lower levels of P1NP (31.4±13.7 
versus 48.9±24.4 ng/ml; p=0.0002) and ß-crosslaps (0.21 ± 0.17 versus 0.34 ± 0.22 ng/ml, p=0.0015) than 
individuals in the control group. There were no significant differences in BMD, bone mineral content or 
TBS. These data suggest that individuals with hypophosphatasemia have an overall reduction of bone 
turnover, even in the absence of overt manifestations of HPP or low BMD.  
 






































































Hypophosphatasia (HPP) is a rare genetic condition caused by loss-of-function mutations of the 
gene that encodes the tissue nonspecitific alkaline phosphatase (ALPL or TNSALP) located on 
chromosome 1p36.12 (1). In humans, there are four alkaline phosphatase (ALP) isoenzymes which are 
encoded by separate genes. Three of them are expressed in a tissue specific distribution and produce the 
intestinal, placental, and germ cell (placental-like) ALP. The fourth gene (ALPL) encodes the tissue-
nonspecific ALP (2)   and is mainly expressed in bone, liver and kidneys. In HPP, deficient 
phosphohydrolase activity leads to extracellular accumulation of its natural substrates, including 
inorganic pyrophosphate (PPi), a potent inhibitor of hydroxyapatite cristal formation and propagation. 
The accumulation of extracelular PPi blocks mineralization and the patients consequently develop 
abnormalities of tissues with a mineralized matrix, including teeth and bone (3). More than 300 
mutations of ALPL have been described and are included in the ALPL gene mutation database (4). Most of 
them are missense mutations and the inheritance pattern can be recessive or dominant.  
The clinical spectrum of HPP is broad and variable within families. Along severe infantile forms, 
there are adult forms with mild manifestations that may be incidentally discovered by the presence of 
low ALP activity in serum. In a previous report (5) we studied 42 individuals with persistent and 
unexplained low levels of ALP and found that 50% of them carried a mutation in the ALPL coding region. 
Although clinical manifestations were usually mild, in about 50% of cases the enzymatic activity was low 
enough to cause the accumulation of phosphorylated substrates. It is still unclear whether individuals 
with persistently low levels of ALP, in the absence of overt manifestations of HPP, present subclinical 
abnormalities of bone remodeling or bone mass. Nevertheless, in the previous  study we unexpectedly 
found low levels of immunoreactive bone ALP (BALP) in patients with low ALP. BALP was determined by 
EIA, a method that measures the protein concentration, not the enzymatic activity. Therefore, that result 




































































a better understanding of the skeletal phenotype of adults with low ALP by analyzing bone mineral 
density (BMD), bone microarchitecture (Trabecular bone score, TBS), and bone turnover markers (BTM).   
 
METHODS 
 We studied 42 unrelated individuals (10 men, 32 women) with persistently low levels of ALP not 
related to drug therapy or other secondary cause. All had at least one determination below 27 U/l and 
none within the normal range (40-160 U/l).  Details about the recruitment have been previously reported 
(5). These included acute diseases, malnutrition, celiac disease, hypothyroidism, parathyroid disease, 
cancer and renal failure, as well as treatment with antiresorptives or glucocorticoids. Most subjects were 
asymptomatic or had mild nonspecific ailments. They did not receive anti-resorptives or other drugs 
known to interfere with bone metabolism. The comparison group included 45 healthy controls (10 men, 
35 women). 
The serum levels of bone turnover markers P1NP and ß-crosslaps were measured with 
automatized chemiluminiscence assays (IDS-iSYS Multi-Discipline Automated Analyzer) in the morning 
after overnight fasting. Sensitivity was 1 ng/ml and 0.033 ng/ml respectively.  The intra-assay coefficient 
of variation (CV) was 2.9 and 4.6%, respectively;  and the interassay CV was 3.2 and 6.2%, respectively.  
To avoid batch-related biases, similar numbers of samples from the patient and control groups were 
included in each run. 
Lumbar spine (L1-L4) and hip BMD were also evaluated by DXA (Hologic QDR 4500, Waltham, 
MA) in 20  individuals with low ALP who consented to be studied. TBS was obtained from DXA scans with 
the use of software v2.1.  
Comparisons between groups were analyzed by Mann-Whitney U and Spearman correlation 








































































Remarkably, patients with low levels of ALP presented lower levels of P1NP and ß-crosslaps than 
individuals in the control group (table 1, and supplementary table S1). The difference was independent of 
age, and consequently it was maintained in the age-adjusted analysis. ß-crosslaps and P1NP levels were 
positively correlated (r=0.64; p<0.001). ß-crosslaps levels were also inversely correlated with serum 
calcium (r=-0.41, p=0.007). However, there were no significant correlations between serum  ß-crosslaps 
or P1NP and serum levels of ALP,  phosphorus,  or pyridoxal phosphate, nor with urine levels of 
phosphoetanolamine.  
ALPL mutations were present in 21 patients (20 heterozygotes and 1 homozygote). The levels of 
ALP were slightly higher in the group without mutation, in comparison with the group with mutations 
detected (30±6 versus 25±6 U/l; p=0.014), both lower than the mean level in controls (64±18 U/l; 
p<0.0001). The presence of an ALPL mutation was not associated with significant differences in BTM 
levels (figure 1). 
We also evaluated BMD in 20 of these individuals with low ALP (6 men 14 women; age 66±16 yr), 
10 of which had an ALPL mutated allele. The results were compared with 80 healthy controls (30 men, 50 
females; age 54±14 yr). Both groups showed similar bone mineral content (BMC) and BMD at the spine 
and the hip. Lumbar Spine BMD was 1.028±0.182 in cases and 0.955±0.163 g/cm2  in controls (p=0.09); 
femoral neck BMD was 0.817±0.156 in cases and 0.775±0.120 g/cm2 in controls (p=0.20); total hip BMD 
was 0.9400.168 and 0.919±0.139 in cases and controls, respectively (p=0.57).  In line with these results, 
there were no significant differences in the age-adjusted BMD between patients with and without ALPL 
mutations. The mean trabecular bone score (TBS) was 1.41±0.09 in patients and 1.37±0.14 in controls 
(p=0.50) in all cases it was higher than 1.20, the lower limit of the normal range.    
 
DISCUSSION 
The incidence of severe HPP is approximately 1 in 300,000 in Europe (6). However, the clinical 




































































infantile periods, while mild forms are sometimes only diagnosed in adulthood or remain undiagnosed.  
Thus, recent studies suggest that less severe forms observed in adults might be substantially more 
frequent.  Mornet et al (7) estimated the prevalence of moderate forms of HPP to be 1/6730.  
The clinical significance of persistently low serum levels of ALP in patients who otherwise do not 
have overt manifestations of HPP is unclear, for those individuals may be asymptomatic or have just mild 
and nonspecific symptoms. Thus, it may be difficult to establish a causal relationship between such 
ailments and the enzymatic defect.  However, it has been suggested that those patients may be at risk of 
developing complications if treated with drugs interfering with bone turnover, including the development 
of atypical femoral fractures related to anti-resorptive therapy (8). 
 Thus, the aim of this study was to investigate if patients with low ALP levels but without overt 
HPP have an abnormal bone homeostasis. We found that patients with persistently low ALP indeed have 
a reduced bone turnover, as assessed by the bone formation marker P1NP and the bone resorption 
marker b-crosslaps. In other words, they have a global alteration of bone metabolism and not just a 
reduced ALP activity. The lower turnover found in this study is consistent with the observations in 
patients with HPP. Most patients with HPP appear to have, along the delayed mineralization with osteoid 
accumulation, low numbers of osteoblasts and osteoclasts, and absence of changes of secondary 
hyperparathyroidism in patients. Similar findings were reported in ALPL knock-out mice (9,10,11,12). 
However, patient heterogeneity appears to exist not only from the clinical point of view, but also from 
the histological perspective, and high osteoblast numbers have been reported in a few patients (13). 
It is worth mentioning that these abnormalities were present in heterozygous patients, which is 
consistent with the results of genetic models. In fact, studies with ALPL knock-out mice showed that even 
heterozygous osteoblasts had an impaired ability to form a mineralized matrix (14).  We did not find clear 
biochemical differences between patients with hypophosphatasemia with mutations of the ALP gene and 
those with hypophosphatasemia but no evidence of gene mutations. However, since we only sequenced 
the coding region of the gene, we cannot exclude the possibility that those patients had mutations in 




































































The mechanisms linking low ALP expression and reduced bone turnover are unclear. It could be 
speculated that the accumulation of osteoid with delayed mineralization could tend to decrease the 
differentiation of osteoblast precursors, through some unidentified feedback mechanisms. This could be 
consistent with the results of bone biopsies in patients with HPP. The intriguing results of a recent study 
showing that an anti-sclerostin monoclonal antibody enhances bone formation markers in patients with 
HPP raise the possibility that Wnt signaling may be involved (15). ALP is usually regarded as a product of 
the osteoblastic lineage. However, other cells may also express the enzyme within the bone 
microenvironment. In particular, ALP activity is also expressed in preosteoclasts. Quite interesting, 
enzyme activity is concentrated in the basolateral membrane in mature resorbing osteoclasts, suggesting 
that ALP might also play some role in bone resorption (16). However, the role of ALP in bone resorption 
remains merely speculative at the present. 
Despite the decreased bone turnover, we did not find differences in BMD or TBS between 
patients and controls, which is consistent with the mostly normal BMD values found in other series of 
adult patients with HPP (17).  
 In 2012, Sutton  et al (8) reported the first case of BP exposure preceding atypical femoral 
fractures (AFFs) in adult HPP. Other authors such as McKiernan et al (18) have also recommended against 
the use of biphosphonates (BP) in patients with suspected HPP. Long term treatment with BPs has been 
associated with AFFs (19). BPs are analogues of PPi and can suppress bone turnover but also deactivate 
ALP (20). Because BPs are analogs of PPi, it has been speculated that HPP patients may be sensitized to 
the effects of BPs. Despite the absence of obvious BMD abnormalities, our findings of low bone 
remodeling in patients with low levels of ALP, even in the absence of overt skeletal manifestations, 
support the recommendation of avoiding antiresorptives such as bisphosphonates in these subjects.  
Our study has some limitations, such as  the smallnumber of individuals with DXA data, and the 
absence of histological analysis. Nevertheless, these results strongly suggest that patients with 




































































remodelling even though they do not present evident clinical skeletal alterations or decreased BMD. This 
might render them more susceptible to anti-resorptive-related adverse effects.   
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Table 1. Main characteristics and bone turnover markers in cases and controls (mean±SD) 
 





Age (yr) 48±14 47±18 ns 
Sex 10M, 32F 10M, 35F ns 
Height (cm) 163±9 163±9 ns 
Weight (kg) 70±17 
 
66±14 ns 
P1NP (ng/ml) 31.4±13.7 48.9±24.4 0.0002 












































































Fig 1. Bone turnover markers in individuals with low ALP levels, without (dashed bars) or with mutations 
(grey solid bars) of the ALPL gene, in comparison with controls (black solid bars). 
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 M
, 
m
a
le
; 
F
, 
fe
m
a
le
; 
LS
, 
lu
m
b
a
r 
sp
in
e
; 
F
N
, 
fe
m
o
ra
l 
n
e
ck
. 
 
N
o
rm
a
l r
a
n
g
e
s 
(m
a
y
 v
a
ry
 w
it
h
 a
g
e
):
 A
LP
 (
A
lk
a
li
n
e
 p
h
o
sp
h
a
ta
se
) 
4
0
-1
6
0
 U
/l
; 
P
LP
 (
P
y
ri
d
o
xa
l p
h
o
sp
h
a
te
) 
2
3
-1
7
3
 n
m
o
l/
l;
 P
E
A
 (
P
h
o
sp
h
o
e
ta
n
o
la
m
in
e
 u
ri
n
e
) 
0
-7
0
 
μ
m
o
l/
g
 c
re
a
ti
n
in
e
; 
C
a
 (
ca
lc
iu
m
) 
8
.1
-1
0
.4
 m
g
/d
l;
 P
 (
P
h
o
sp
h
o
ru
s)
 2
.3
-4
.0
 m
g
/l
);
 P
1
N
P
 (
P
ro
p
e
p
ti
d
e
 o
f 
ty
p
e
 1
 p
ro
co
ll
a
g
e
n
) 
1
8
-1
0
2
 n
g
/m
l;
 C
T
X
 (
ß
-c
ro
ss
la
p
s)
 0
.0
5
-
0
.0
8
3
 n
g
/m
l.
  
M
o
st
 f
ra
ct
u
re
s 
w
e
re
 r
e
la
te
d
 t
o
 t
ra
u
m
a
 (
w
it
h
 t
h
e
 e
xc
e
p
ti
o
n
 o
f 
th
e
 o
n
e
 m
a
rk
e
d
 w
it
h
 a
n
 a
st
e
ri
sk
).
 
